Assessment of biochemical aspirin resistance at rest and immediately after exercise testing

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 1, 2007, Pages 9-13

  Gulmez, Oyku ^a   Yildirir, Aylin ^a   Bal, Ugur ^a   Konas, Necibe Didem ^a   Aydinalp, Alp ^a   Demir, Ozlem ^a   Atar, Ilyas ^a   Ertan, Cagatay ^a   Ozin, Bulent ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Aspirin resistance; Exercise; Platelet function analyzer

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGEN TYPE 1; CORASPIN; NORADRENALIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG SENSITIVITY; EXERCISE TEST; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REST; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

AGED; ASPIRIN; DRUG RESISTANCE; EXERCISE; EXERCISE TEST; FEMALE; HUMANS; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; REST;

EID: 33845807450     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328010bd26     Document Type: Article

References (32)

1. Bhatt DL, Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am 2000; 84:163-179; ix.
2. Patrono C, Coller B, Dalen JE, Fitzgerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119:39S-63S.
3. Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 2005; 142:370-380.
4. Mason PJ, Freedman JE, Jacobs AK. Aspirin resistance: current concepts. Rev Cardiovasc Med 2004; 5:156-163.
5. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003; 1:1710-1713.
6. Mason PJ, Jacobs AK, Freedman JE. Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005; 46:986-993.
7. Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls. Eur Heart J 1997; 18:807-815.
8. Macchi L, Brizard A, Christiaens L, Christiaens I, Herpin D. Assessment of platelet activation after exercise using a standardized whole blood flow cytometry assay. Thromb Res 2002; 106:169-170.
9. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9:407-415.
10. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:81-106; erratum 1540.
11. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86; erratum 141.
12. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349-360.
13. Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kesser CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202.
14. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88:230-235.
15. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994; 89:1951-1957.
16. Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res 2000; 99:487-494.
17. Christiaens L, Macchi L, Herpin D, Coisne D, Duplantier C, Allal J, et al. Resistance to aspirin in vitro at rest and during exercise in patients with angiographically proven coronary artery disease. Thromb Res 2002; 108:115-119.
18. Wang JS, Jen CJ, Kung HC, Lin L, Hsiue TR, Chen H. Different effects of strenuous exercise and moderate exercise on platelet function in men. Circulation 1994; 90:2877-2885.
19. Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, Michelson AD. Effect of strenuous exercise on platelet activation state and reactivity. Circulation 1993; 88:1502-1511.
20. Rostrup M, Westheim A, Refsum HE, Holme I, Eide I. Arterial and venous plasma catecholamines during submaximal steady-state exercise. Clin Physiol 1998; 18:109-115.
21. el-Sayed MS. Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Med 1996; 22:282-298.
22. Kamath S, Blann AD, Lip GY. Platelet activation: assessment and quantification. Eur Heart J 2001; 22:1561-1571.
23. Mammen EF, Comp PC, Gosselin R, Geenberg C, Hoots WK, Kessler CM, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24:195-202.
24. Eikelboom JW, Hirsh J, Weitz JI, Weitz JL, Johnston M, Yi Q, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105:1650-1655.
25. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41:961-965.
26. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43:1122-1126.
27. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993; 71:397-403.
28. Rowland M, Riegelman S, Harris PA, Sholkoff SD, Eyring EJ. Kinetics of acetylsalicylic acid disposition in man. Nature 1967; 215:413-414.
29. Lavy G. Pharmacokinetics of salicylate elimination in man. J Pharm Sci 1965; 54:959-967.
30. Alex M, Spergling M, Muhlestein B, Steinhubl S, Serebruany V. Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis 2004; 15:295-301.
31. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schror K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13:37-40.
32. Michenson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al., on behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3:1309-1311.